SCHEMBL21569110

SCHEMBL21569110

N#Cc1ccc2nc(NC(=O)Nc3cccc(Oc4ccccc4)c3)sc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.57
▸ KMT2A Q03164 6/20 0.57
▸ NPC1 O15118 5/20 0.57
▸ MAPT P10636 5/20 0.57
▸ MEN1 O00255 5/20 0.57
▸ POLB P06746 3/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ NFKB1 P19838 2/20 0.57
▸ NFKB2 Q00653 2/20 0.57
▸ RELA Q04206 2/20 0.57
▸ LMNA P02545 2/20 0.57
▸ HDAC6 Q9UBN7 1/20 0.57
▸ DYRK1A Q13627 4/20 0.56
▸ DYRK1B Q9Y463 2/20 0.55
▸ USP2 O75604 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ GSK3B P49841 1/20 0.54
▸ GAA P10253 1/20 0.52
▸ RIPK3 Q9Y572 3/20 0.50
▸ RIPK1 Q13546 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21568852 0.89 RAB9A (0.67) RAB9AKMT2ANPC1MAPTMEN1
SCHEMBL23256870 0.88 DYRK1A (0.70) RAB9AKMT2ANPC1MAPTMEN1
SCHEMBL23256883 0.87 DYRK1A (0.66) RAB9AKMT2ANPC1MAPTMEN1
SCHEMBL21568073 0.84 DYRK1A (0.62) RAB9AKMT2ANPC1MAPTMEN1
SCHEMBL21551996 0.83 DYRK1A (0.61) RAB9AKMT2ANPC1MAPTMEN1
SCHEMBL21568259 0.83 LMNA (0.66) RAB9AKMT2ANPC1MAPTMEN1
SCHEMBL21568251 0.82 KMT2A (0.50) RAB9AKMT2ANPC1MAPTMEN1
SCHEMBL23256882 0.81 DYRK1A (0.58) RAB9AKMT2ANPC1MAPTMEN1
SCHEMBL21568288 0.81 DYRK1A (0.55) RAB9AKMT2ANPC1MAPTMEN1
SCHEMBL21568046 0.81 GSK3B (0.65) RAB9AKMT2ANPC1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731985-B2 Compositions and methods for treating cancer HB THERAPEUTICS INC. (US) 2023-08-22 — — US disclosed
US-20210115064-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER HB THERAPEUTICS INC. (US) 2021-04-22 — — US disclosed
WO-2019217509-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER HB THERAPEUTICS INC. (US) 2019-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731985-B2 Compositions and methods for treating cancer VHL, TP53, NUDT1 RAB9A 3882/4885KMT2A 623/4885NPC1 424/4885
US-20210115064-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER VHL, TP53, NUDT1 RAB9A 4161/4885KMT2A 512/4885NPC1 749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback